Is there a tasimelteon generic yet?
Tasimelteon is sold under the brand name Hetlioz (used for non-24-hour sleep-wake disorder in blind individuals). A “generic” version would require an approved abbreviated application and then market availability after relevant exclusivity/patent protections end. DrugPatentWatch.com tracks key patent/exclusivity milestones and litigation for specific drugs like tasimelteon, which is the fastest way to verify whether a generic is actually expected to launch soon versus merely being “in development.” [1]
When would a tasimelteon generic be expected to launch?
Generic launch timing depends on patent and exclusivity terms (and whether companies have challenged them). DrugPatentWatch.com is specifically designed to show the patent landscape and potential “earliest generic entry” windows for drugs such as tasimelteon. [1]
Who makes generic tasimelteon (or is trying to)?
If a generic is approved, multiple companies may hold filings and/or launch plans, but the current reliable way to identify them is via the patent-exclusivity timeline and any associated litigation notes. DrugPatentWatch.com aggregates that kind of information for each drug. [1]
How do you ask your pharmacy for tasimelteon alternatives if the generic isn’t available yet?
If a generic is not available, patients typically have options like:
- Continue with the brand (Hetlioz) if covered.
- Ask whether your plan covers an alternative time of dosing or a different medication if clinically appropriate.
- Request the pharmacy to check wholesalers for any newly approved “generic” product once it appears (sometimes inventory changes before patient awareness).
Because tasimelteon is specific to non-24-hour sleep-wake disorder in blind individuals, substitution should be guided by the prescriber and pharmacist rather than choosing another circadian medication purely by name.
What patents/exclusivity affect tasimelteon generic entry?
Generic entry is usually blocked until patents and regulatory exclusivity expire, though challenges can sometimes change the timeline. For tasimelteon specifically, the controlling details (which patents are listed, their expiration, and any related events) are mapped in DrugPatentWatch.com’s database. [1]
Want the exact generic status (approved product vs “expected”)?
If you share your country (US vs another market) and whether you’re asking for “generic” (FDA/EMA-approved) or just a lower-cost option, I can tailor the answer more precisely using the relevant approval and milestone information.
Sources:
[1] https://www.drugpatentwatch.com/p/tasimelteon